No biomarker
No biomarker
|
Anal Carcinoma
Anal Carcinoma
|
MIXE
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Anal Carcinoma
Anal Carcinoma
|
TPF
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Anal Carcinoma
Anal Carcinoma
|
pembrolizumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Anal Carcinoma
Anal Carcinoma
|
nivolumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Anal Carcinoma
Anal Carcinoma
|
FOLFOX
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Anal Carcinoma
Anal Carcinoma
|
carboplatin + paclitaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Anal Carcinoma
Anal Carcinoma
|
FOLFCIS
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Anal Carcinoma
Anal Carcinoma
|
cisplatin + 5-fluorouracil
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Anal Carcinoma
Anal Carcinoma
|
mFOLFOX6
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Anal Carcinoma
Anal Carcinoma
|
capecitabine
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Anal Carcinoma
Anal Carcinoma
|
5-fluorouracil
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Anal Carcinoma
Anal Carcinoma
|
DCF
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Anal Carcinoma
Anal Carcinoma
|
INCMGA0012
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
Anal Carcinoma
Anal Carcinoma
|
pembrolizumab
Sensitive: C1 - Off-label
|
CD163 expression
CD163 expression
|
Anal Carcinoma
Anal Carcinoma
|
toripalimab
Sensitive: C3 – Early Trials
|
CD4 expression
CD4 expression
|
Anal Carcinoma
Anal Carcinoma
|
toripalimab
Sensitive: C3 – Early Trials
|
PD-L1 expression
PD-L1 expression
|
Anal Carcinoma
Anal Carcinoma
|
toripalimab
Sensitive: C3 – Early Trials
|
PD-L1 amplification + PD-L2 amplification + TMB-H
PD-L1 amplification + PD-L2 amplification + TMB-H
|
Anal Carcinoma
Anal Carcinoma
|
pembrolizumab
Sensitive: C4 – Case Studies
|
